• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP-As Ebola cases near 10,700, WHO recommends adding 2 Bundibugyo vaccines to clinical trial

Lance

MPH, CSP & CIT Retired, CHMM Emeritus

As Ebola cases near 10,700, WHO recommends adding 2 Bundibugyo vaccines to clinical trial​

Mary Van Beusekom, MS

Today at 3:10 p.m.
Ebola


As the Ebola case and death total in the African outbreak continue to rise, expert groups convened by the World Health Organization (WHO) have recommended adding two candidate Bundibugyo Ebola virus vaccines to the ongoing Tumaini clinical trial.

The outbreak case total now stands at 10,699, including 5,202 deaths, the US Centers for Disease Control and Prevention reported today.

Yesterday, the UK government said that a British healthcare worker was being repatriated for medical treatment after testing positive for Ebola in outbreak epicenter, the Democratic Republic of Congo (DRC). The unidentified patient was in stable condition, The Guardian reports.

On October 3, Kenya released five Ebola patients from the hospital after tests showed they had cleared the virus, the Ministry of Health told the AP. Two patients are still receiving supportive care in the hospital.

The ministry also said 46 contacts of the country’s first Ebola patient were released after 21 days of quarantine. This follows last week’s release of 20 contacts. The 52 contacts remaining in quarantine are expected to be released next week. Kenya has reported eight cases, including two deaths, with no new cases since October 19.

Bundibugyo vaccines to be tested amid outbreak for first time​

Expert groups convened by the WHO recommended adding two new Ebola vaccine candidates to the ongoing Tumaini clinical trial in the DRC, the WHO said yesterday in a news release.

This will be the first time vaccines targeting the Bundibugyo Ebola virus, which is causing the current outbreak, will be tested during an outbreak of the strain.
Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control.
Tedros Adhanom Ghebreyesus, PhD
The vaccine candidates are ChAdOx1, developed by the University of Oxford and the Serum Institute of India, and Moderna’s mRNA-1469. They will enter the trial after national approvals. “Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control,” WHO Director-General Tedros Adhanom Ghebreyesus, PhD, said in the release.

Tumaini was designed to test multiple vaccine candidates within a single trial using a ring-vaccination approach that enrolls contacts of infected people. Ervebo, a vaccine used against the Zaire Ebola virus, is the first vaccine being evaluated to assess efficacy against the Bundibugyo virus.

Research into potential treatments is also progressing, the WHO said. The WHO-sponsored PARTNERS trial is assessing whether the monoclonal antibody MBP134, the antiviral drug remdesivir, or a combination of both can boost survival among Bundibugyo patients.

The monoclonal antibody maftivimab will soon be added to the trial as a potential treatment. A complementary post-exposure prophylaxis study with the antiviral medication obeldevisir is already under way.
 
Back
Top Bottom